An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol.
BACKGROUND: Atrial fibrillation (AF) is an independent risk factor for stroke and a significant predictor of mortality. Evidence-based guidelines for stroke prevention in AF recommend antithrombotic therapy corresponding to the risk of stroke. In practice, many patients with AF do not receive the a...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2013
|
| _version_ | 1797071932527476736 |
|---|---|
| author | Apenteng, P Murray, E Holder, R Hobbs, R Fitzmaurice, D |
| author_facet | Apenteng, P Murray, E Holder, R Hobbs, R Fitzmaurice, D |
| author_sort | Apenteng, P |
| collection | OXFORD |
| description | BACKGROUND: Atrial fibrillation (AF) is an independent risk factor for stroke and a significant predictor of mortality. Evidence-based guidelines for stroke prevention in AF recommend antithrombotic therapy corresponding to the risk of stroke. In practice, many patients with AF do not receive the appropriate antithrombotic therapy and are left either unprotected or inadequately protected against stroke. The purpose of the Global Anticoagulant Registry in the FIELD (GARFIELD) is to determine the real-life management and outcomes of patients newly diagnosed with non-valvular AF. METHODS/DESIGN: GARFIELD is an observational, international registry of newly diagnosed AF patients with at least one additional investigator-defined risk factor for stroke. The aim is to enrol 55,000 patients at more than 1000 centres in 50 countries worldwide. Enrolment will take place in five independent, sequential, prospective cohorts; the first cohort includes a retrospective validation cohort. Each cohort will be followed up for 2 years. The UK stands to be a significant contributor to GARFIELD, aiming to enrol 4,582 patients, and reflecting the care environment in which patients with AF are managed. The UK protocol will also focus on better understanding the validity of the two main stroke risk scores (CHADS2 and CHA2DS2VASC) and the HAS-BLED bleeding risk score, in the context of a diverse patient population. DISCUSSION: The GARFIELD registry will describe how therapeutic strategies, patient care, and clinical outcomes evolve over time. This study will provide UK-specific comprehensive data that will allow a range of evaluations both at a national level and in relation to global data and contribute to a better understanding of AF management in the UK. TRIAL REGISTRATION: ClinicalTrial.gov: NCT01090362. |
| first_indexed | 2024-03-06T23:00:25Z |
| format | Journal article |
| id | oxford-uuid:61e7b258-62b2-4386-966f-2613d646f3b2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:00:25Z |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:61e7b258-62b2-4386-966f-2613d646f3b22022-03-26T18:02:55ZAn international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:61e7b258-62b2-4386-966f-2613d646f3b2EnglishSymplectic Elements at OxfordBioMed Central2013Apenteng, PMurray, EHolder, RHobbs, RFitzmaurice, D BACKGROUND: Atrial fibrillation (AF) is an independent risk factor for stroke and a significant predictor of mortality. Evidence-based guidelines for stroke prevention in AF recommend antithrombotic therapy corresponding to the risk of stroke. In practice, many patients with AF do not receive the appropriate antithrombotic therapy and are left either unprotected or inadequately protected against stroke. The purpose of the Global Anticoagulant Registry in the FIELD (GARFIELD) is to determine the real-life management and outcomes of patients newly diagnosed with non-valvular AF. METHODS/DESIGN: GARFIELD is an observational, international registry of newly diagnosed AF patients with at least one additional investigator-defined risk factor for stroke. The aim is to enrol 55,000 patients at more than 1000 centres in 50 countries worldwide. Enrolment will take place in five independent, sequential, prospective cohorts; the first cohort includes a retrospective validation cohort. Each cohort will be followed up for 2 years. The UK stands to be a significant contributor to GARFIELD, aiming to enrol 4,582 patients, and reflecting the care environment in which patients with AF are managed. The UK protocol will also focus on better understanding the validity of the two main stroke risk scores (CHADS2 and CHA2DS2VASC) and the HAS-BLED bleeding risk score, in the context of a diverse patient population. DISCUSSION: The GARFIELD registry will describe how therapeutic strategies, patient care, and clinical outcomes evolve over time. This study will provide UK-specific comprehensive data that will allow a range of evaluations both at a national level and in relation to global data and contribute to a better understanding of AF management in the UK. TRIAL REGISTRATION: ClinicalTrial.gov: NCT01090362. |
| spellingShingle | Apenteng, P Murray, E Holder, R Hobbs, R Fitzmaurice, D An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. |
| title | An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. |
| title_full | An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. |
| title_fullStr | An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. |
| title_full_unstemmed | An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. |
| title_short | An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. |
| title_sort | international longitudinal registry of patients with atrial fibrillation at risk of stroke garfield the uk protocol |
| work_keys_str_mv | AT apentengp aninternationallongitudinalregistryofpatientswithatrialfibrillationatriskofstrokegarfieldtheukprotocol AT murraye aninternationallongitudinalregistryofpatientswithatrialfibrillationatriskofstrokegarfieldtheukprotocol AT holderr aninternationallongitudinalregistryofpatientswithatrialfibrillationatriskofstrokegarfieldtheukprotocol AT hobbsr aninternationallongitudinalregistryofpatientswithatrialfibrillationatriskofstrokegarfieldtheukprotocol AT fitzmauriced aninternationallongitudinalregistryofpatientswithatrialfibrillationatriskofstrokegarfieldtheukprotocol AT apentengp internationallongitudinalregistryofpatientswithatrialfibrillationatriskofstrokegarfieldtheukprotocol AT murraye internationallongitudinalregistryofpatientswithatrialfibrillationatriskofstrokegarfieldtheukprotocol AT holderr internationallongitudinalregistryofpatientswithatrialfibrillationatriskofstrokegarfieldtheukprotocol AT hobbsr internationallongitudinalregistryofpatientswithatrialfibrillationatriskofstrokegarfieldtheukprotocol AT fitzmauriced internationallongitudinalregistryofpatientswithatrialfibrillationatriskofstrokegarfieldtheukprotocol |